Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026
PR Newswire•21/10/2026•16:05 ET
0
Key Highlights
- ➤Nuvation Bio (NUVB) will report Q3 2026 financial results November 4, 2026
- ➤Conference call and webcast scheduled for 4:30 p.m. ET
- ➤Pipeline includes taletrectinib, safusidenib, and a drug-drug conjugate program
Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026 PR Newswire
NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Wednesday, November 4, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the third quarter of 2026.
Get started
Create a free account to read the full story.